Sun Pharmaceutical Industries, India’s top pharmaceutical company, on Tuesday, launched Favipiravir under the brand name of ‘FluGuard’ in the market for treating mild to moderate coronavirus cases. ‘FluGuard’ will be available in the market from this week with a price of Rs. 35 per tablet.
Sun Pharma with the help of the government and the medical community aims to provide the drug to all the patients suffering from COVID-19 across the country.
“With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response,” Kirti Ganorkar the CEO of India Business of Sun Pharma, said on the launch.
Favipiravir v/s Remdesivir
- Favipiravir is known for its antiviral action against all subtypes of influenza virus strains.
- For treating influenza, patients are given a 1600 mg dose of Favipiravir on Day 1 and about 600 mg dose from day 2 to day 5.
- It was originally developed under the brand name Avigan by a Japanese company Fujifilm Holdings Corp.
- On June 19 it received a green signal for emergency use in treating patients with mild to moderate Covid-19 disease by the Drug Controller General of India (DCGI).
- Not only in India, but it is also marketed in Russia and China.
- To date, remdesivir is a potential therapy for COVID-19.
- It is the only antiviral drug that has received a green signal for Emergency Use Authorization (EUA) by the USFDA for the treatment in the severe cases of COVID-19.
- Remdesivir is the key ingredient in ‘JUBI-R’. however, ‘JUBI-R’ can only be used in emergency cases with the high supervision of the medical practitioner.
Some other Favipiravir dealers in India
Several drug-making companies in India are developing or selling favipiravir in the market including Cipla, Hetero Labs, and Glenmark Pharmaceuticals. Meanwhile, due to the increased competition in the market Glenmark’s FabiFlu (favipiravir) decreased its selling prices from Rs. 103 to Rs. 75 apiece.